Therefore, despite the ongoing clinical challenges associated with JAK2 inhibition in the setting of MPNs, JAK2 inhibition may still reduce symptomatic burden of JAK2-altered ALL and improve outcomes by bridging more patients to Allo-SCT. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.